U.S. Medical Equipment Stock News

If you are wondering whether Northern Oil and Gas at around US$28.84 is offering fair value or a potential mismatch between price and underlying worth, you are not alone. The stock has recent returns of 4.8% over 7 days, 5.4% over 30 days, 31.0% year to date and 2.4% over 1 year, which naturally raises questions about how much is already reflected in the price. Recent coverage has focused on Northern Oil and Gas in the context of its role within the broader energy sector and its position as...

Regulatory milestone and why it matters for TMC the metals (NasdaqGS:TMC) TMC the metals (NasdaqGS:TMC) is back in focus after the National Oceanic and Atmospheric Administration found its consolidated application for Clarion Clipperton Zone exploration and commercial recovery to be in substantial compliance with U.S. deep seabed regulations. See our latest analysis for TMC the metals. The regulatory progress arrives after a sharp reset in the share price, with a 36.25% 90 day share price...

In March 2026, Soleno Therapeutics updated its corporate bylaws, continued outreach with a CEO presentation at the Longwood Healthcare Leaders conference, and faced an investor class action lawsuit alleging inadequate disclosure of safety concerns around its Prader‑Willi syndrome therapy DCCR/Vykat XR. This combination of governance changes, legal scrutiny and discussion of a slower Vykat XR launch puts renewed focus on how safety perceptions and patient adoption may shape Soleno’s...

Caterpillar (NYSE:CAT) is supplying natural gas generators to power the Monarch Compute Campus in West Virginia, one of the world's largest planned AI data center sites. The facility, developed by Nscale and Microsoft, is planned to deliver over 1.35GW of AI compute capacity and is designed to scale to 8GW. Caterpillar's G3500 generators are contracted to provide independent on site power for this multi gigawatt AI data center build. The company also has a separate global framework agreement...

Why Penske Automotive Group (PAG) Is On Investors’ Radar Today Penske Automotive Group (PAG) has come into focus after a stretch of weaker recent share performance, with the stock showing negative returns over the past week, month, past 3 months and year to date. That softer run contrasts with the company’s longer multi year track record. The 3 year and 5 year total returns remain positive, prompting some investors to reassess how current pricing lines up with the underlying business. See our...

Relay Therapeutics (RLAY) is back in focus after presenting new Phase 1/2 ReDiscover data for zovegalisib plus fulvestrant, where a 400 mg twice-daily fed dose showed efficacy and safety in line with earlier higher-dose findings. See our latest analysis for Relay Therapeutics. The updated zovegalisib data arrives after a powerful swing in sentiment, with Relay Therapeutics’ 1 year total shareholder return of 223.86% contrasting with a 5 year total shareholder return loss of 71.07%. Its 30 day...

Alcoa (NYSE:AA) is seeing stronger interest from aluminum buyers following supply chain disruption linked to the closure of the Strait of Hormuz. Customers are seeking alternative suppliers outside the Gulf region, and Alcoa reports a surge in inquiries for its aluminum products. The company is benefiting from higher aluminum prices and premiums in the United States as buyers adjust sourcing plans. For investors watching industrial metals, this shift puts Alcoa, a major upstream aluminum...

Microvast Holdings (MVST) is back in focus after reaffirming and expanding its long running battery partnership with Iveco Group in Europe, alongside releasing 2025 results, 2026 guidance, and an auditor warning on going concern risks. See our latest analysis for Microvast Holdings. Despite a series of material updates including the expanded Iveco partnership, 2025 results, 2026 guidance and the going concern warning, Microvast’s recent share price performance has been weak. The 30 day share...

If you are wondering whether Viridian Therapeutics at around US$26.98 is offering good value or asking too much, you are in the right place. The stock has recently seen mixed returns, with a 7 day move of 5.9% decline and a 30 day return of 4.0% decline, while still sitting on a 76.8% gain over the past year and 12.1% decline year to date. Recent news coverage has focused on Viridian Therapeutics as a biotech name that continues to attract attention from investors watching the sector. This...

Coherent (COHR) is back in focus after high profile product showcases at OFC 2026 and an expanded multiyear partnership with Nvidia, including a sizeable investment and a long term AI photonics supply commitment. See our latest analysis for Coherent. The recent Nvidia partnership and OFC 2026 showcases come after a powerful run, with a 30.52% year to date share price return and a very large 1 year total shareholder return. This hints that investors see rising potential in Coherent’s AI...

If you are wondering whether Abbott Laboratories at around US$105 per share looks like an opportunity or a value trap, the starting point is understanding what the current price actually reflects. The stock has seen a 2.4% decline over the past week, a 6.9% decline over the last month, and a 15.1% decline year to date, with a 15.0% decline over the past year and a 14.1% gain over three years. These moves are set against a backdrop of ongoing attention on large healthcare names, with...

In March 2026, UGG, a division of Deckers Brands, launched its Spring 2026 Golden Collection, turning its iconic cold-weather classics into warm-weather sandals and clogs available through UGG.com, UGG stores, and select wholesale partners. The collection’s emphasis on year-round use of the UGG aesthetic, recycled materials, and contrasting textures highlights the brand’s push to extend its signature comfort beyond winter and deepen engagement with both existing and new customers. Next,...

What Argan’s Recent Share Move Tells You Argan (AGX) has drawn fresh attention after a strong price move over the past 3 months, with the stock showing a 45.54% total return and a 14.42% gain over the past month. See our latest analysis for Argan. That recent 30 day share price return of 14.42% builds on a strong 90 day run of 45.54%, while the 1 year total shareholder return of 296% and very large 3 year and 5 year total shareholder returns suggest momentum has been firmly positive for some...

AOP Health’s decision to run its rare disease and intensive care operations on Veeva Systems (VEEV) cloud platforms highlights how deeply Veeva’s software can be embedded across clinical, regulatory, safety, and commercial workflows. See our latest analysis for Veeva Systems. Even with news like the AOP Health rollout highlighting real world use of its platforms, Veeva’s share price tells a mixed story. A 7 day share price return of 2.9% is set against a 1 year total shareholder return...

Biogen recently saw a federal securities class action certified for investors who acquired its shares between June 8, 2021 and July 12, 2021, while also highlighting investigational therapies such as litifilimab for cutaneous lupus erythematosus and salanersen for spinal muscular atrophy at major medical meetings. Together, the class action certification and progress in autoimmune and neuromuscular drug pipelines underscore how Biogen’s legal exposure and innovation efforts are evolving in...

In recent weeks, oil prices have climbed sharply following the Iran conflict, pushing Brent crude above US$100 per barrel and refocusing attention on efficient US producers such as EOG Resources. The key angle for investors is how EOG’s reputation for low-cost, high-productivity wells may allow it to convert higher prices into additional excess cash to reinvest and return to shareholders. We’ll now examine how this period of elevated oil prices could influence EOG Resources’ existing...

TransMedics Group (TMDX) is drawing attention after a recent share pullback, with reports of insider selling by senior executives and directors coinciding with continued pressure on the stock, despite generally supportive analyst commentary. See our latest analysis for TransMedics Group. The recent weakness in TransMedics Group’s share price, including a 14.28% 1 month share price return decline and a 7.16% negative year to date share price return, sits against a much stronger 64.95% 1 year...

GE Vernova and Hitachi have been selected to supply BWRX-300 small modular reactors for a new US Japan nuclear program. The reactors are planned for deployment in Tennessee and Alabama as part of a wider $40b bilateral investment initiative. The selection positions GE Vernova at the center of a high profile cross border nuclear buildout focused on SMR technology. For investors watching NYSE:GEV, this project ties the company’s nuclear capabilities to a sizeable capital program that goes...

Wondering whether Hewlett Packard Enterprise at around US$21.69 is offering genuine value or just headline appeal? This article breaks down what the current price might be implying about the business. The stock has recent returns of 0.5% over 7 days and 0.6% over 30 days, set against a year to date return of a 10.3% decline, and gains of 37.7% over 1 year, 64.4% over 3 years and 55.8% over 5 years. Recent coverage of Hewlett Packard Enterprise has focused on how investors are reassessing...

StoneCo triggered by recent performance StoneCo (STNE) has been on many watchlists after a recent stretch of negative short term returns, including an 18.8% decline over the past month and a 6.6% decline over the past 3 months. See our latest analysis for StoneCo. Despite the recent 18.8% 1 month share price decline to US$13.35 and softer short term momentum, StoneCo still shows a 20.3% 1 year total shareholder return and a 49.3% 3 year total shareholder return. If you are reassessing your...

Recent returns put Welltower in focus Welltower (WELL) has come into focus after a mixed run in its share price, with a 1 day decline of 4.9% and a roughly 6% pullback over the past month. See our latest analysis for Welltower. While the recent 1 day share price return of roughly 5% and the 7 day and 30 day share price returns in the same range point to fading near term momentum, the 1 year, 3 year and 5 year total shareholder returns of 35.95%, very large and very large respectively...

Wondering whether Bob's Discount Furniture is a bargain or a value trap at around US$12.49? This article breaks down what the current price might be implying about the business. The stock has seen sharp recent moves, with a 7 day return of an 18.9% decline and a 30 day return of a 37.2% decline, while the year to date return sits at a 26.6% decline. These swings have put Bob's Discount Furniture back on the radar for investors who are reassessing what they are willing to pay for retailers...

If you are wondering whether Accenture's current share price really reflects its underlying value, this article walks through the key signals you can use to judge it for yourself. Accenture last closed at US$199.99, with returns of 1.7% over the past week, a 10.6% decline over the past month, a 23.1% decline year to date, and a 33.0% decline over the past year. These moves sit against a backdrop where Accenture has been in the spotlight for its role as a major global IT and consulting player...

If you are wondering whether Copart's share price around US$32.86 is starting to look appealing or still has more room to fall, you are not alone. The stock has seen a 3.6% decline over the last week, a 12.7% decline over the past month, and a 13.0% decline year to date, adding to a 38.7% decline over the past year that may be changing how investors view its potential and risk. Recent coverage has focused on Copart's share price performance and how current levels compare with longer term...